Cagrilintide
Also known as: Cagri, 0833, CagriSema (combination with semaglutide), DACRA (dual amylin and calcitonin receptor agonist)
Long-acting amylin analogue; dual amylin receptor (AMYR) and calcitonin receptor (CTR) agonist (DACRA)
What it is
Cagrilintide is an experimental weight-loss drug being studied in combination with semaglutide for obesity and type 2 diabetes. It mimics amylin, a hormone that signals fullness after eating, working alongside GLP-1 pathways to reduce appetite and body weight. Not FDA-approved; Phase 3 clinical trials ongoing.
The scientific side
Cagrilintide is a lipidated, long-acting amylin analogue engineered for once-weekly subcutaneous dosing. It functions as a dual agonist at amylin receptors (AMYRs) and the calcitonin receptor (CTR), activating Gs signalling pathways through both receptor types. Structurally, cagrilintide adopts a similar "bypass" binding mode in both receptors, with key molecular features including an F23 residue anchoring the peptide at the receptor transmembrane bundle, an E14–R17 intramolecular salt bridge enhancing helical stability, and a C-terminal P37 interaction with the receptor extracellular domain. These features collectively enable non-selective binding and activation across both receptor types. In the central nervous system, long-term cagrilintide treatment upregulates prolactin-releasing hormone (Prlh) expression in nucleus of the solitary tract Calcr/Prlh neurons; knockdown of DVC Prlh abrogates the effects of cagrilintide (but not semaglutide) on body weight in rats. Amylin and its analogues promote satiation, slow gastric emptying, suppress glucagon secretion, and influence both homeostatic and hedonic feeding mechanisms via central nervous system pathways. When combined with semaglutide (a GLP-1 receptor agonist) as CagriSema, the two agents act through complementary but distinct pathways, producing additive or synergistic effects on weight loss and glycaemic control.
Class: Long-acting amylin analogue; dual amylin receptor (AMYR) and calcitonin receptor (CTR) agonist (DACRA)
Administration & storage
- Administration
- Subcutaneous injectiononce-weekly (PMID: 34798060)Subcutaneous injectiononce-weeklyself-administered (PMID: 34798060)Subcutaneous injectiononce-weekly in combination with semaglutide 2.4 mg (PMID: 33894838)Subcutaneous injectiononce-weekly as fixed-dose combination CagriSema (PMID: 405444334054443142251859422518604225185642009015)
- Storage
- No storage conditions for cagrilintide are described in the reviewed abstracts. The potential for amyloid fibril aggregation in amylin-based peptide therapeutics is noted as a formulation consideration requiring proper storage, manipulation, and usage to avoid high-molecular-weight products.
- Cautions
- Gastrointestinal adverse events (nausea, vomiting, constipation, diarrhoea) were the most frequently reported adverse events across all clinical studies of cagrilintide, occurring in 41–63% of cagrilintide monotherapy recipients vs 32% with placebo in the phase 2 dose-finding trial.,Gastrointestinal adverse events were more common with CagriSema than with semaglutide or placebo; GI AE-related discontinuation was highest with high-dose CagriSema among novel amylin-based therapies in network meta-analysis.,Administration-site conditions were significantly more frequent with CagriSema combination therapy vs semaglutide monotherapy (RR 3.27; 95% CI 1.27–8.46).,Cagrilintide monotherapy was associated with a higher risk of serious adverse events compared to semaglutide monotherapy in a meta-analysis (RR 1.83; 95% CI 1.03–3.24).,Amylin-based therapeutic peptides may be prone to high-molecular-weight product (amyloid/amorphous) formation; proper formulation and handling are important to preserve biological activity and avoid immune reactions.,Cagrilintide did not produce clinically relevant QTc prolongation at doses up to 4.5 mg in a dedicated thorough QT study, indicating no identified increased risk of ventricular tachyarrhythmias.,No dose adjustment appears required for renal or hepatic impairment based on pharmacokinetic studies, though sample sizes were small.,Sterile technique is required for all subcutaneous injections to prevent injection-site contamination.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Semaglutide has been included in the World Anti-Doping Agency's monitoring program since 2024; cagrilintide is noted to warrant consideration for anti-doping monitoring programs but its current WADA status is not…
Not stated in reviewed literature — requires manual verification
What it's studied for
- Weight management in adults with overweight or obesity (without diabetes) Human RCT
- Cagrilintide-semaglutide (2.4 mg each) produced mean body weight change of -20.4% vs -3.0% with placebo (estimated difference -17.3 pp; p<0.001). Gastrointestinal adverse events in 79.6% (cagrilintide-semaglutide) vs 39.9% (placebo), mostly transient and mild-to-moderate. PMID 40544433 Garvey WT et al. N Engl J Med. 2025 (REDEFINE 1, phase 3a, 68 weeks, n=3417)
- Cagrilintide monotherapy 0.3–4.5 mg once-weekly produced mean weight reductions of 6.0%–10.8% vs 3.0% with placebo (p<0.001 for all doses). Cagrilintide 4.5 mg produced greater weight loss than liraglutide 3.0 mg (10.8% vs 9.0%; p=0.03). PMID 34798060 Lau DCW et al. Lancet. 2021 (Phase 2, dose-finding, 26 weeks, n=706, cagrilintide monotherapy)
- Cagrilintide 1.2 and 2.4 mg combined with semaglutide 2.4 mg produced mean body weight reductions of 15.7% and 17.1% at week 20, vs 9.8% with placebo + semaglutide. PMID 33894838 Enebo LB et al. Lancet. 2021 (Phase 1b, cagrilintide + semaglutide 2.4 mg, n=95)
- Weight management in adults with overweight or obesity with type 2 diabetes Human RCT
- Cagrilintide-semaglutide 2.4 mg each produced mean body weight change of -13.7% vs -3.4% with placebo (estimated difference -10.4 pp; p<0.001). 73.5% of CagriSema patients achieved HbA1c ≤6.5% vs 15.9% with placebo. Gastrointestinal adverse events in 72.5% vs 34.4% (placebo). PMID 40544431 Davies MJ et al. N Engl J Med. 2025 (REDEFINE 2, phase 3a, 68 weeks, n=1206)
- CagriSema produced mean HbA1c change of -2.2 pp vs -1.8 pp (semaglutide) and -0.9 pp (cagrilintide). Mean body weight change was -15.6% (CagriSema) vs -5.1% (semaglutide) and -8.1% (cagrilintide); p<0.0001 for CagriSema vs both. PMID 37364590 Frias JP et al. Lancet. 2023 (Phase 2, 32 weeks, n=92, T2D)
- Glycaemic control as add-on to basal insulin in type 2 diabetes Human RCT
- CagriSema 2.4 mg each produced HbA1c reduction of -2.33% vs -0.66% (placebo) (ETD -1.68 pp; p<0.0001) as add-on to basal insulin. Bodyweight reduced 10–12%. No severe hypoglycaemia reported. PMID 42251856 Rosenstock J et al. Lancet. 2026 (REIMAGINE 3, phase 3, 40 weeks, n=274)
- Glycaemic control in early-stage type 2 diabetes managed with diet and exercise Human RCT
- CagriSema 2.4 mg each produced HbA1c change of -1.8 pp vs -0.1 pp (placebo) (ETD -1.7 pp; p<0.0001). Bodyweight change: -13.8% (CagriSema 2.4 mg) vs -1.4% (placebo) (ETD -12.4 pp; p<0.0001). PMID 42251860 Aroda VR et al. Lancet Diabetes Endocrinol. 2026 (REIMAGINE 1, phase 3a, 40 weeks, n=189)
- Glycaemic control in type 2 diabetes versus semaglutide or cagrilintide monotherapy Human RCT
- CagriSema 2.4 mg each produced HbA1c change of -1.91 pp vs -1.75 pp with semaglutide 2.4 mg (ETD -0.16 pp; p=0.0035). Most common adverse events were gastrointestinal disorders. PMID 42251859 Buse JB et al. Lancet Diabetes Endocrinol. 2026 (REIMAGINE 2, phase 3, 68 weeks, n=2713)
- Weight management in east Asian adults with overweight or obesity (with or without T2D) Human RCT
- CagriSema produced mean bodyweight change of -18.4% vs -11.9% (semaglutide) (ETD -6.5 pp; p<0.0001). Adverse events in 87% (CagriSema) vs 84% (semaglutide), most commonly gastrointestinal. PMID 42009015 Yamauchi T et al. Lancet Diabetes Endocrinol. 2026 (REDEFINE 5, phase 3a, 68 weeks, Japan and Taiwan, n=331)
- Blood pressure reduction in adults with overweight or obesity Human RCT
- CagriSema 2.4 mg/2.4 mg produced systolic BP change of -10.9 vs -2.8 mmHg (placebo) and diastolic BP change of -5.4 vs -1.7 mmHg. 63.0% of CagriSema participants reached BP targets vs 32.0% (placebo). 39.6% in CagriSema group decreased or stopped antihypertensive medication vs 18.8% (placebo). PMID 41328546 Verma S et al. Hypertension. 2026 (REDEFINE 1 secondary/post hoc analysis, n=3417)
- Metabolic dysfunction-associated steatohepatitis (MASH) with clinically significant fibrosis (exploratory arm) Human RCT
- In an exploratory arm, CagriSema 2.4 mg plus semaglutide 2.4 mg was not substantially different from placebo for the primary endpoint (improvement in liver fibrosis ≥1 stage and no worsening of MASH). Semaglutide 2.4 mg monotherapy showed nominally significant benefit vs placebo (p=0.024). PMID 42456707 Loomba R et al. Lancet Gastroenterol Hepatol. 2026 (Phase 2 RCT, 52 weeks, n=99 in CagriSema arm)
- Structural and mechanistic characterisation (receptor binding) In vitro only
- Cryo-EM and X-ray structures of cagrilintide bound to AMYR1, AMYR2, AMYR3, and CTR-Gs complexes determined. Cagrilintide has an amylin-like binding mode but induces distinct conformational dynamics at calcitonin-family receptors compared with other peptides. PMID 40204768 Cao J et al. Nat Commun. 2025
- Cryo-EM structures of cagrilintide bound to AMYR-Gs and CTR-Gs complexes determined. Key features: F23 anchoring at TM bundle level, E14–R17 intramolecular salt bridge, C-terminal P37 interaction with receptor ECD. Non-selective Gs activation confirmed. PMID 40847076 Gu YM et al. Acta Pharmacol Sin. 2026
- In vitro effects on skeletal muscle mitochondrial function In vitro only
- In C2C12 myotubes, cagrilintide transiently reduced basal respiration (21–28%) and ATP production (24–31%) at 48 h, along with reductions in Complexes I, III, and IV protein expression, all resolving by 5 days. Similar transient reductions observed in human myotubes (30–62%) at 48 h. PMID 41852165 Old V et al. J Cachexia Sarcopenia Muscle. 2026
- Preclinical (animal) obesity and metabolic disease models Animal studies only
- In DIO rats, cagrilintide (0833) sub-chronically reduced food intake and body weight, potentiating semaglutide's effects. Primarily reduced fat mass. A tool compound (0839, 95% sequence homology) had comparable effects and is available through Novo Nordisk Compound Sharing. PMID 40628316 Gabery S et al. Life Sci. 2025 (DIO rats and mice)
- Long-term cagrilintide treatment upregulates Prlh expression in NTS Calcr/Prlh neurons across rodents, macaques, and humans. Knockdown of DVC Prlh abrogates cagrilintide but not semaglutide effects on body weight in rats. PMID 42207966 Ludwig MQ et al. Nature Metabolism. 2026 (rats, mice, macaques)
- Obesity-associated cancer risk (subgroup analysis of coagonists including cagrilintide) Human RCT
- Subgroup analysis of coagonists (tirzepatide, cotadutide, and cagrilintide) showed significantly reduced overall obesity-associated cancer risk (RR 0.43; 95% CI 0.19–0.97). Overall AOMs did not reduce cancer risk. PMID 41189318 Li C et al. Obesity (Silver Spring). 2026 (meta-analysis of 25 RCTs, n=40,731)
- Cardiac repolarisation safety (thorough QT study) Human RCT
- Cagrilintide dose-escalated to 4.5 mg once-weekly did not result in clinically relevant QTcF prolongation; upper limit of 90% CI for placebo-adjusted QTcF changes fell below 10 ms at all time points. PMID 39426704 Gabe MBN et al. Diabetes Obes Metab. 2024 (thorough QT study, n=105)
- Pharmacokinetics in renal or hepatic impairment Human RCT
- Single doses of cagrilintide 0.6 or 0.9 mg showed no clinically relevant differences in AUC, Cmax, or other PK parameters across normal, mild, moderate, or severe renal or hepatic impairment groups. Dose adjustment not considered warranted. PMID 42228334 Nielsen MJF et al. Clin Pharmacokinet. 2026 (Phase 1 studies; renal n=33, hepatic n=32)
- In vitro metabolic profiling and anti-doping detection In vitro only
- Cagrilintide underwent N-terminal and C-terminal degradation in human skin S9 fraction, kidney S9 fraction, and biological fluids, yielding multiple stable metabolic products. Metabolites predicted from in vitro experiments were confirmed in authentic post-administration rat plasma samples. LC-MS/MS detection approach PMID 41702251 Alhalabi H et al. J Pharm Biomed Anal. 2026
Protocol
No community protocol on record. In clinical studies, Cagrilintide was dosed at 0.3, 0.6, 1.2, 2.4, or 4.5 mg once-weekly (dose-finding) subcutaneous injection (PMID 34798060).
All studies (24)
- PMID 33894838 Human RCT
Weight management in adults with overweight or obesity (without diabetes) - PMID 34798060 Human RCT
Weight management in adults with overweight or obesity (without diabetes) - PMID 37364590 Human RCT
Weight management in adults with overweight or obesity with type 2 diabetes - PMID 39426704 Human RCT
Cardiac repolarisation safety (thorough QT study) - PMID 40544431 Human RCT
Weight management in adults with overweight or obesity with type 2 diabetes - PMID 40544433 Human RCT
Weight management in adults with overweight or obesity (without diabetes) - PMID 41189318 Human RCT
Obesity-associated cancer risk (subgroup analysis of coagonists including cagrilintide) - PMID 41328546 Human RCT
Blood pressure reduction in adults with overweight or obesity - PMID 42009015 Human RCT
Weight management in east Asian adults with overweight or obesity (with or without T2D) - PMID 42228334 Human RCT
Pharmacokinetics in renal or hepatic impairment - PMID 42251856 Human RCT
Glycaemic control as add-on to basal insulin in type 2 diabetes - PMID 42251859 Human RCT
Glycaemic control in type 2 diabetes versus semaglutide or cagrilintide monotherapy - PMID 42251860 Human RCT
Glycaemic control in early-stage type 2 diabetes managed with diet and exercise - PMID 42456707 Human RCT
Metabolic dysfunction-associated steatohepatitis (MASH) with clinically significant fibrosis (explor - PMID 34715595
- PMID 38582303
10 nmol/kg (cagrilintide combined with bGLP-10 in DIO mice) Not specified (animal study) (animal) - PMID 40204768 In vitro only
Structural and mechanistic characterisation (receptor binding) - PMID 40628316 Animal studies only
Preclinical (animal) obesity and metabolic disease models - PMID 40847076 In vitro only
Structural and mechanistic characterisation (receptor binding) - PMID 41702251 In vitro only
In vitro metabolic profiling and anti-doping detection - PMID 41834765
- PMID 41852165 In vitro only
In vitro effects on skeletal muscle mitochondrial function - PMID 42175595
- PMID 42207966 Animal studies only
Preclinical (animal) obesity and metabolic disease models